引言胰腺导管腺癌（PDAC）是当前对免疫治疗响应最差的实体瘤之一。其免疫抑制性微环境、抗原表达的异质性以及免疫细胞浸润不足等特征，严重限制了免疫检查点抑制剂等传统免疫疗法的疗效。因此，亟需开发能够有效激活患者自身免疫系统的新型免疫治疗策略。在此背景下 ...

A recent publication in Nature Medicine describes a novel immunotherapy targeting pancreatic cancer that has shown promising ...

This interview discusses how BCMA-directed CAR T-cell therapy in multiple myeloma may be more effective when administered ...

The use of base editing to generate universal off-the-shelf CAR T cells induced durable remissions -- up to 36 months in one ...

Eleven patients with refractory autoimmune hemolytic anemia (AIHA) were all brought into drug-free remission with CAR T-cell ...

Wang also acknowledges emerging platforms such as CAR NK cells and in vivo CAR T technologies but notes these remain ...

CAR T-cell therapy has the potential to revolutionise how we treat certain types of cancer by genetically engineering someone’s own immune cells to attack the disease – but it is also cumbersome and ...

Researchers have discovered a way to help aging intestines heal themselves using CAR T-cell therapy, targeting senescent ...